The Human Cancer PrimaCell™ 2: Biliary Tract Tumor Cells is for rapid (7-10 days) isolation and growth of human biliary tumor cells from human biliary tract tumor tissues. This system features an optimal condition of tissue dissociation system, Cancer OptiTDS™ that yields 5-7 times of single cells more than most of the tissue dissociation protocols published in the literature. In addition, this system ensures a high viability of the target cells with improved gradient contained in the culture medium.

Human Cancer PrimaCell™ 2 System (Cat No. 2-96025):
Human Cancer PrimaCell™ 2: Biliary Tumor Cells Protocols
Human Cancer Tissue Preparation Buffer 2: Biliary Tumor Cells
Human Cancer OptiTDS™ 2: Tissue Dissociation System
Human Cancer PrimaCell™ 2: Biliary Tumor Cells Growth Medium
Human Cancer PrimaCell™ 2: Biliary Tumor Cells Growth Supplements with Serum (for 500 ml medium)

References:

[1] Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T. Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. Cancer Sci. 2010 Apr;101(4):882-8. Epub 2009 Dec 8.
[2] Finzi L, Shao MX, Paye F, Housset C, Nadel JA. Lipopolysaccharide initiates a positive feedback of epidermal growth factor receptor signaling by prostaglandin E2 in human biliary carcinoma cells. J Immunol. 2009 Feb 15;182(4):2269-76.
[3] Pietersen AM, Rutjes SA, van Tongeren J, Vogels R, Wesseling JG, Noteborn MH. The tumor-selective viral protein apoptin effectively kills human biliary tract cancer cells. J Mol Med (Berl). 2004 Jan;82(1):56-63. Epub 2003 Nov 28.